What is the difference between vascular dementia and alzheimers

1. Tomlinson BE., Blessed G., Roth M. Observations on the brains of demented old people. J Neurol Sci.1970;11:205–242. [PubMed] [Google Scholar]

2. Hachinski VC., Lassen NA., Marshall J. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet.1974;2:207–209. [PubMed] [Google Scholar]

3. Hachinski VC., Miff LD., Zilhka E., et al. Cerebral blood flow in dementia. Arch Neurol.1975;32:632–637. [PubMed] [Google Scholar]

4. Perry E., Tomlinson BE., Blessed G., Bergmann K., Gibson PH., Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ.1978;2:1457–1459. [PMC free article] [PubMed] [Google Scholar]

5. Perry EK., Perry RH., Blessed G., Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol.1978;4:273–277. [PubMed] [Google Scholar]

6. Bartus RT., Emerich DF. Cholinergic markers in Alzheimer disease. JAMA.1999;282:2208–2209. [PubMed] [Google Scholar]

7. Lin L., Georgievska B., Mattsson A., Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci U S A.1999;96:12108–12113. [PMC free article] [PubMed] [Google Scholar]

8. Isacson O., Lin L. Cholinergic modulation of amyloid processing and dementia in animal models of Alzheimer's disease. Ann N Y Acad Sci.2000;920:309–314. [PubMed] [Google Scholar]

9. McKahnn G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology.1984;34:939–944. [PubMed] [Google Scholar]

10. Fisher CM. Dementia in cerebrovascular disease. In: Toole JF, Siekert RG, Whisnant JP, eds. Cerebral Vascular Disease: Sixth Conference.New York, NY: Grune-Stratton;1968:232–236. [Google Scholar]

11. Deutsch JA. The cholinergic synapse and the site of memory. Science.1971;174:788–794. [PubMed] [Google Scholar]

12. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience.1986;19:1–28. [PubMed] [Google Scholar]

13. Perry EK., Gibson PH., Blessed G., Perry RH., Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci.1977;34:247–265. [PubMed] [Google Scholar]

14. Babikian V., Ropper AH. Binswanger's disease: a review. Stroke.1987;18:2–12. [PubMed] [Google Scholar]

15. Erkinjuntti T. Types of multi-infarct dementia. Acta Neurol Scand.1987;75:391–399. [PubMed] [Google Scholar]

16. Roman GC. Senile dementia of the Binswanger type: a vascular form of dementia in the elderly. JAMA.1987;258:1782–1788. [PubMed] [Google Scholar]

17. Chui HC., Victoroff Jl., Margolin D., Jagust W., Shankle R., Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology.1992;42:473–480. [PubMed] [Google Scholar]

18. Roman GC., Tatemichi TK., Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology.1993;43:250–260. [PubMed] [Google Scholar]

19. Skoog I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother.1997;51:367–375. [PubMed] [Google Scholar]

20. Mirra SS., Heyman A., McKeel D., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology.1991;41:479–486. [PubMed] [Google Scholar]

21. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis.2002;13(suppl 2):7–10. [PubMed] [Google Scholar]

22. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis.2002;13(suppl 2):11–15. [PubMed] [Google Scholar]

23. Schmidt R., Schmidt H., Kapeller P., Lechner A., Fazekas F. Evolution of white matter lesions. Cerebrovasc Dis.2002;13(suppl 2):16–20. [PubMed] [Google Scholar]

24. Meyer JS., Xu G., Thornby J., Chowdhury MH., Quach M. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease? Stroke.2002;33:1981–1985. [PubMed] [Google Scholar]

25. Snowdon DA., Greiner LH., Mortimer JA., Riley KP., Greiner PA., Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA.1997;277:813–817. [PubMed] [Google Scholar]

26. Henon H., Durieu I., Guerouaou D., Lebert F., Pasquier F., Leys D. Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology.2001;57:1216–1222. [PubMed] [Google Scholar]

27. Kalaria RN., Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord.1999;13(suppl 3):S115–S123. [PubMed] [Google Scholar]

28. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging.2000;21:321–330. [PubMed] [Google Scholar]

29. Ott A., Stolk RP., Hofman A., van Harskamp F., Grobbee DE., Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia.1996;39:1392–1397. [PubMed] [Google Scholar]

30. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiological study. Neurobiol Aging.2000;21:153–160. [PubMed] [Google Scholar]

31. Bots ML., van Kooten F., Haverkate F., et al. Coagulation and fibrinolysis markers and risk of dementia: the Dutch vascular factors in dementia study. Haemostasis.1998;28:216–222. [PubMed] [Google Scholar]

32. Kalmijn S., Launer LJ., Lindemans J., Bots JL., Hofman A., Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol.1999;150:283–289. [PubMed] [Google Scholar]

33. Ott A., Breteler MM., de Bruyne MC., van Harskamp F., Grobbee DE., Hofman A. Atrial fibrillation and dementia in a population-based study: the Rotterdam Study. Stroke.1997;28:316–321. [PubMed] [Google Scholar]

34. Graves AB., van Duijn CM., Chandra V., et al. for the EURODEM Risk Factors Research Group. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-controlled studies. Int Epidemiol. 1991;20:S48–S57. [PubMed] [Google Scholar]

35. Ott A., Breteler MM., van Harskamp F., et al. Prevalence of Alzheimer's disease and vascular dementia association with education: the Rotterdam Study. BMJ.1995;310:970–973. [PMC free article] [PubMed] [Google Scholar]

36. Hofman A., Ott A., Breteler MMB., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet.1997;349:151–154. [PubMed] [Google Scholar]

37. Breteler MM., Bots ML., Ott A., Hofman A. Risk factors for vascular disease and dementia. Haemostasis.1998;28:167–173. [PubMed] [Google Scholar]

38. Kivipelto M., Helkala EL., Hanninen T., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population-based study. BMJ.2001;322:1447–1451. [PMC free article] [PubMed] [Google Scholar]

39. Tyas SL., Manfreda J., Strain LA., Montgomery PR. Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol.2001;30:590–597. [PubMed] [Google Scholar]

40. Kalmijn S. Dietary fat intake and risk of incident dementia in the Rotterdam Study. Ann Neurol.1997;42:776–782. [PubMed] [Google Scholar]

41. Notkola IL., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology.1998;17:14–20. [PubMed] [Google Scholar]

42. Diaz-Arrastia R. Hyperhomocysteinemia: a new risk factor for Alzheimer's disease? Arch Neurol.1998;55:1–2. [PubMed] [Google Scholar]

43. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S., Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet.2002;359:1283–1290. [PubMed] [Google Scholar]

44. Skyler JS., Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev.2002;18(suppl 3):S21–S26. [PubMed] [Google Scholar]

45. Meigs JB. Epidemiology of the metabolic syndrome. 2002. Am J Manag Care.2002;8(suppl):S283-S293–S292 -S296. [PubMed] [Google Scholar]

46. Holmes C., Cairns N., Lantos P., et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry.1999;174:45–50. [PubMed] [Google Scholar]

47. Neuropathology Group of the Medical Research Council Cognitive Function and Aged Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales, Lancet.2001;357:169–175. [PubMed] [Google Scholar]

48. Zekry D., Hauw JJ., Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc.2002;50:1431. [PubMed] [Google Scholar]

49. Moroney JT., Bagiella E., Desmond DW., et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology.1997;49:1096–1105. [PubMed] [Google Scholar]

50. Swan GE., LaRue A., Carmelli D., Reed TE., Fabsitz RR. Decline in cognitive performance in aging twins. Heritability and biobehavioral predictors from the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol.1992;49:476–481. [PubMed] [Google Scholar]

51. Launer LJ., White LR., Petrovitch H., Ross GW., Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology.2001;57:1447–1452. [PubMed] [Google Scholar]

52. Bonarek M., Barberger GP., Letenneur L., Deschamps V., Dubroka B., Datrigues JF. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology.2000;19:141–148. [PubMed] [Google Scholar]

53. Kabara JJ. A critical review of brain cholesterol metabolism. Prog Brain Res.1973;40:363–382. [PubMed] [Google Scholar]

54. Morell P., Jurevics H. Origin of cholesterol in myelin. Neurochem Res.1996;21:463–470. [PubMed] [Google Scholar]

55. Dietschy JM., Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol.2001;12:105–112. [PubMed] [Google Scholar]

56. Roheim PS., Carey M., Forte T., Vega GL. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA.1979;76:4646–4649. [PMC free article] [PubMed] [Google Scholar]

57. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science.1988;240:622–631. [PubMed] [Google Scholar]

58. Simons M., Keller P., Dichgans J., Schulz JB. Cholesterol and Alzheimer's disease. Is there a link? Neurology.2001;57:1089–1093. [PubMed] [Google Scholar]

59. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti CG., Simons K. Cholesterol depletion inhibits the generation of amyloid in hippocampal neurons. Proc Natl Acad Sci U S A.1998;95:6460–6464. [PMC free article] [PubMed] [Google Scholar]

60. Frears E., Stephens D., Walters C., Davies H., Austen B. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport.1999;10:1699–1705. [PubMed] [Google Scholar]

61. Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effects on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A.2001;98:5815–5820. [PMC free article] [PubMed] [Google Scholar]

62. Wolozin B., Kellman W., Rousseau P., Celesia CC., Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol.2000;57:1439–1443. [PubMed] [Google Scholar]

63. Jick H., Zornberg GL., Jick SS., Seshadri S., Drachman DA. Statins and the risk of dementia, Lancet.2000;356:1627–1631. [PubMed] [Google Scholar]

64. Crisby M., Carlson LA., Winblan B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord.2002;16:131–136. [PubMed] [Google Scholar]

65. Cucchiara B., Kasner SE. Use of statins in CNS disorders. J Neurol Sci.2001;187:81–89. [PubMed] [Google Scholar]

66. Mahley RW., Rail SCJr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet.2000;1:507–537. [PubMed] [Google Scholar]

67. Eichner JE., Dunn ST., Perveen G., Thompson DM., Stewart KE., Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol.2002;155:487–495. [PubMed] [Google Scholar]

68. Chapman J., Korczyn A., Karussis DM., Michaelson DM. The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology.2001;57:1482–1485. [PubMed] [Google Scholar]

69. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci.1994;17:525–530. [PubMed] [Google Scholar]

70. Prince M., Lovestone S., Cervilla J., et al. The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology.2000;54:397–402. [PubMed] [Google Scholar]

71. Haraki T., Takegoshi T., Kitoh C., et al. Carotid artery intima-media thickness and brachial artery flow-mediated vasodilation in asymptomatic Japanese male subjects amongst apolipoprotein E phenotypes. J Intern Med.2002;252:114–120. [PubMed] [Google Scholar]

72. Djousse L., Myers RH., Province MA., et al. Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke.2002;33:1357–1361. [PubMed] [Google Scholar]

73. Humphries SE., Talmud PJ., Hawe E., Bolla M., Day IN., Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet.2001;358:115–119. [PubMed] [Google Scholar]

74. Lambert JC., Brousseau T., Defosse V., et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations: the ECTIM study. Hum Mol Genet.2000;9:57–61. [PubMed] [Google Scholar]

75. Lahoz C., Schaefer EJ., Cupples LA., et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis.2001;154:529–537. [PubMed] [Google Scholar]

76. Scuteri A., Bos AJ., Zonderman AB., Brant LJ., Lakatta EG., Fleg JL. Is the apoE4 allele an independent predictor of coronary events? Am J Med.2001;110:28–32. [PubMed] [Google Scholar]

77. Slooter AJ., Tang MX., van Duijn CM., et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA.1997;277:818–821. [PubMed] [Google Scholar]

78. Premkumar DR., Cohen DL., Hedera P., Friedland RP., Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol.1996;148:2083–2095. [PMC free article] [PubMed] [Google Scholar]

79. Jarrett RJ. Epidemiology and public health aspects of non-insulindependent diabetes mellitus. Epidemiol Rev.1989;11:151–171. [PubMed] [Google Scholar]

80. Stegmayr B., Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia.1995;38:1061–1068. [PubMed] [Google Scholar]

81. Skoog I. Risk factors for vascular dementia: a review. Dementia.1994;5:137–144. [PubMed] [Google Scholar]

82. Tatemichi TK., Desmond DW., Paik M., et al. Clinical determinants of dementia related to stroke. Ann Neurol.1993;33:568–575. [PubMed] [Google Scholar]

83. Luchsinger JA., Tang MX., Stern Y., Shea S., Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Ami J Epidemiol.2001;154:635–641. [PubMed] [Google Scholar]

84. Peila R., Rodriguez BL., Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. The Honolulu-Asia Aging Study. Diabetes.2002;51:1256–1262. [PubMed] [Google Scholar]

85. Landin K., Blennow K., Wallin A., Gottfries CG. Low blood pressure and blood glucose levels in Alzheimer's disease. Evidence for a hypometabolic disorder? J Intern Med.1993;233:357–363. [PubMed] [Google Scholar]

86. Nielson KA., Nolan JH., Berchtold NC., Sandman CA., Mulnard RA., Cotman CW. Apolipoprotein-E genotype of diabetic dementia patients: is diabetes rare in Alzheimer's disease? J Am Geriatr Soc.1996;44:897–904. [PubMed] [Google Scholar]

87. Vanhanen M., Kuusisto J., Koivisto K., et al. Type 2 diabetes and cognitive function in a non-demented population. Acta Neurol Scand.1999;100:97–101. [PubMed] [Google Scholar]

88. Curb JD., Rodriguez BL., Abbott RD., et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology.1999;52:971–975. [PubMed] [Google Scholar]

89. Munch G., Mayer S., Michaelis J., et al. Influence of advanced glycation endproducts and AGE inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim BiophysActa.1997;1360:17–29. [PubMed] [Google Scholar]

90. Dickson DW., Sinicropi S., Yen SH., et al. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging.1996;17:733–733. [PubMed] [Google Scholar]

91. Mukherjee A., Song E., Kihiko-Ehmann M., et al. Insulin hydrolyzes amyloid peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci.2000;20:8745–8749. [PMC free article] [PubMed] [Google Scholar]

92. Qiao Qiu W., Walsh DM., Ye Z., et al. Insulin-degrading enzyme regulates extracellular levels of amyloid p-protein by degradation. J Biol Chem.1998;273:32730–32738. [PubMed] [Google Scholar]

93. Stolk RP., Breteler MM., Ott A., et al. Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care.1997;20:792–795. [PubMed] [Google Scholar]

94. Craft S., Dagogo-Jack SE., Wiethop BV., et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci.1993;107:926–940. [PubMed] [Google Scholar]

95. Palovcik RA., Phillips Ml., Kappy MS., Raizada MK. Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res.1984;309:187–191. [PubMed] [Google Scholar]

96. Craft S., Newcomer J., Kanne S., et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging.1996;17:123–130. [PubMed] [Google Scholar]

97. Unger J., McNeill TH., Moxley RT., White M., Moss A., Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience.1989;31:143–157. [PubMed] [Google Scholar]

98. Petrovich H., White LR., Izmirilian G., et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS, Honolulu-Asia Aging Study. Neurobiol Aging.2000;21:57–62. [PubMed] [Google Scholar]

99. Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta Neuropathol (Bert).1984;62:178–184. [PubMed] [Google Scholar]

100. Johansson BB. Pathogenesis of vascular dementia: the possible role of hypertension. Dementia.1994;5:174–176. [PubMed] [Google Scholar]

101. Wallin A., Sjogren M., Edman A., Blennow K., Regland B. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT whitematter changes in dementia. Eur Neurol.2000;44:229–235. [PubMed] [Google Scholar]

102. Wallin A. The overlap between Alzheimer's disease and vascular dementia: the role of white matter changes. Dement Geriatr Cogn Disord.1998;9(suppl 1):30–35. [PubMed] [Google Scholar]

103. Launer LJ., Masaki K., Petrovich H., Foley D., Havlik RJ. The association between midlife blood pressure levels and late life cognitive function. The Honolulu-Asia Aging Study. JAMA.1995;274:1846–1851. [PubMed] [Google Scholar]

104. Peila R., White LR., Petrovich H., et al. Joint effect of the APOE gene and midlife systolic blood pressure on late life cognitive impairment. The Honolulu Asia Aging Study. Stroke.2001;32:2882–2889. [PubMed] [Google Scholar]

105. Carmelli D., Swan GE., Reed T., et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology.1998;50:1580–1585. [PubMed] [Google Scholar]

106. Elias MF., Wolf PA., D'Agostino RB., Cobb J., White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham study. Am J Epidemiol.1993;138:353–364. [PubMed] [Google Scholar]

107. Skoog I. 15-year longitudinal study of blood pressure and dementia. Lancet.1996;347:1141–1145. [PubMed] [Google Scholar]

108. Swan GE., LaRue A., Carmelli D., Reed TE., Fabsitz RR. Decline in cognitive performance in aging twins. Heritability and biobehavioral predictors from the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol.1992;49:476–481. [PubMed] [Google Scholar]

109. Clare Morris M. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol.2001;58:1640–1646. [PubMed] [Google Scholar]

110. Kilander L., Nyman H., Boberg M., Hansson L., Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension.1998;31:780–786. [PubMed] [Google Scholar]

111. Kalmijn S., Feskens EJ., Launer LJ., Kromhout D. Cerebrovascular disease, the ApoE4 allele and cognitive decline in a community-based study of elderly men. Stroke.1996;27:2230–2235. [PubMed] [Google Scholar]

112. Swain RA., St Clair L. The role of folic acid in deficiency states and prevention of disease. J Earn Pract.1997;44:138–144. [PubMed] [Google Scholar]

113. Elkind MS., Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol.1998;18:429–440. [PubMed] [Google Scholar]

114. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull.1999;55:578–592. [PubMed] [Google Scholar]

115. Leblhuber F., Walli J., Artner-Dworzak E., et al. Hyperhomocysteinemia in dementia. J Neural Transm.2000;107:1469–1474. [PubMed] [Google Scholar]

116. Seshadri S., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med.2002;346:476–483. [PubMed] [Google Scholar]

117. Vermeer SE., van Dijk EJ., Koudstaal PJ., et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol.2002;51:285–289. [PubMed] [Google Scholar]

118. De Groot JC., De Leeuw FE., Qudkerk M., et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol.2002;52:335–341. [PubMed] [Google Scholar]

119. Lipton SA., Kim WK., Choi YB., et al. Neurotoxicity associated with dual actions of homocysteine at the A/-methyl-D-aspartate receptor. Proc Natl Acad Sci U SA.1997;94:5923–5928. [PMC free article] [PubMed] [Google Scholar]

120. Kruman II., Culmsee C., Chan SL., et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci.2000;20:6920–6926. [PMC free article] [PubMed] [Google Scholar]

121. Kruman II., Kumaravel TS., Lohani A., et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci.2002;22:1752–1762. [PMC free article] [PubMed] [Google Scholar]

122. Cheng A., Braunstein JB., Dennison C., Nass C., Blumenthal RS. Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy. Clin Cardiol.2002;25:205–212. [PMC free article] [PubMed] [Google Scholar]

123. Stampfer MJ., Hu FB., Manson JE., Rimm EB., Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med.2000;343:16–22. [PubMed] [Google Scholar]

124. Platz EA., Willet WC., Colditz GA., Rimm EB., Spiegelman D., Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control.2000;11:579–588. [PubMed] [Google Scholar]

125. Lindsay J., Laurin D., Verreault R., et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol.2002;156:445–453. [PubMed] [Google Scholar]

126. Laurin D., Verreault R., Lindsay J., MacPherson K., Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol.2001;58:498–504. [PubMed] [Google Scholar]

127. Friedland RP., Fritsch T., Smyth KA., et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy controlgroup members. Proc Natl Acad Sci U S A.2001;98:3440–3445. [PMC free article] [PubMed] [Google Scholar]

128. Ruitenberg A., van Swieten JC., Witteman JC., et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet.2002;359:281–286. [PubMed] [Google Scholar]

Is Alzheimer's and vascular dementia the same thing?

Does vascular dementia lead to Alzheimer's?

What are the first signs of vascular dementia?

Which is more common Alzheimer's or vascular dementia?